Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

42.32USD
21 Aug 2014
Price Change (% chg)

$0.18 (+0.43%)
Prev Close
$42.14
Open
$42.29
Day's High
$42.52
Day's Low
$42.20
Volume
925,120
Avg. Vol
1,379,823
52-wk High
$43.27
52-wk Low
$32.70

ABT.N

Chart for ABT.N

About

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a portfolio of science-based health care products. Abbott operates in four business segments: diagnostics, medical devices, nutritionals and generic pharmaceuticals. Geographically, 30% of its revenue is generated in the United... (more)

Overall

Beta: 0.64
Market Cap (Mil.): $63,365.88
Shares Outstanding (Mil.): 1,503.70
Dividend: 0.22
Yield (%): 2.09

Financials

  ABT.N Industry Sector
P/E (TTM): 30.28 33.58 34.30
EPS (TTM): 1.39 -- --
ROI: 6.82 18.87 18.12
ROE: 9.41 19.50 18.84
Search Stocks

Mylan presses on with tax-inversion Abbott deal

- Political opposition to tax-inversion deals will not stop Mylan Inc's purchase of some non-U.S. businesses from Abbott Laboratories , Chief Executive Heather Bresch said, even as some companies have backed away from such tax arrangements.

07 Aug 2014

UPDATE 2-Mylan presses on with tax-inversion Abbott deal

* CEO: Tax-inversion deals do not stop companies paying US taxes

07 Aug 2014

Abbott beats profit estimate, infant formulas rebound

- Abbott Laboratories Inc reported better-than-expected quarterly earnings on Wednesday as demand for its recently-recalled infant formulas began to recover and profit margins improved for other business segments.

16 Jul 2014

BRIEF-Abbott CEO says growth for nutritional products, pharmaceuticals "getting back on track"

July 16 - Abbott Laboratories : * CEO, in conference call, says growth for nutritional products, pharmaceuticals

16 Jul 2014

Sanofi held talks with Abbott, Mylan about mature drugs: document

PARIS - Sanofi has held talks with Abbott Laboratories , Mylan and private equity firms over the possible sale of a 6.3 billion euro ($8.5 billion) portfolio of mature drugs, according to an internal document seen by Reuters.

16 Jul 2014

UPDATE 1-Sanofi held talks with Abbott, Mylan about mature drugs -document

* Portfolio has sales of 2.1 bln eur, enterprise value 6.3 bln eur

16 Jul 2014

Sanofi held talks with Abbott, Mylan on mature drugs -document

PARIS, July 16 - Sanofi has held talks with Abbott Laboratories, Mylan and private equity firms over the possible sale of a 6.3 billion euro ($8.5 billion) portfolio of mature drugs, according to an internal document seen by Reuters.

16 Jul 2014

Mylan to buy Abbott generics, cut taxes, in $5.3 billion deal

- Generic drugmaker Mylan Inc said on Monday it would buy Abbott Laboratories' branded specialty and generics business in developed markets outside the United States in a $5.3 billion deal that will bolster its product line and also cut its tax bill.

14 Jul 2014

Abbott CEO says interested in acquiring more medical devices

- Abbott Laboratories <ABT.N) said on Monday it is interested in bolstering its line of medical devices, but it was becoming increasingly difficult to find appropriate and affordable products.

14 Jul 2014

UPDATE 2-Mylan to buy Abbott generics, cut taxes, in $5.3 bln deal

(Adds analyst comments, details of deal, company background, stock prices)

14 Jul 2014

Competitors

  Price Change
Johnson & Johnson (JNJ.N) $104.19 +0.98
Pfizer Inc. (PFE.N) $28.82 -0.07
Novartis AG (NOVN.VX) CHF81.10 +0.25
Merck & Co., Inc. (MRK.N) $58.85 -0.63
Sanofi SA (SASY.PA) €80.59 +1.31
AstraZeneca plc (AZN.L) 4,411.50p +126.50
GlaxoSmithKline plc (GSK.L) 1,434.50p +17.00
Eli Lilly and Co (LLY.N) $62.03 +0.02
Amgen, Inc. (AMGN.OQ) $132.53 -0.15
Medtronic, Inc. (MDT.N) $64.10 -0.05

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: S&P Capital IQ Quantitative Report
$92.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks